Antares seeks US FDA nod for Otrexup in RA, psoriasis
This article was originally published in Scrip
Executive Summary
Antares is seeking the US FDA's approval to market the firm's subcutaneously administered methotrexate product Otrexup as a treatment for rheumatoid arthritis (RA), poly-articular-course juvenile RA and moderate to severe psoriasis.